Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cytomx Thera 151 OYSTER POINT BLVD.SUITE 400 SOUTH SAN FRANCISCO CA 94080 USA

www.cytomx.com Employees: 121 P: 650-515-3185 F: 650-351-0353

Sector:

Medical

Description:

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.

Key Statistics

Overview:

Market Capitalization, $K 745,514
Enterprise Value, $K 707,464
Shares Outstanding, K 169,435
Annual Sales, $ 138,100 K
Annual Net Income, $ 31,870 K
Last Quarter Sales, $ 5,960 K
Last Quarter Net Income, $ -14,230 K
EBIT, $ 23,240 K
EBITDA, $ 19,700 K
60-Month Beta 2.37
% of Insider Shareholders 6.60%
% of Institutional Shareholders 67.77%
Float, K 158,252
% Float 93.40%
Short Interest 17,188
Short Float 10.14%
Short Volume Ratio 0.44

Growth:

1-Year Return 281.42%
3-Year Return 175.00%
5-Year Return -32.82%
5-Year Revenue Growth 140.22%
5-Year Earnings Growth 116.81%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.09 on 11/06/25
Next Earnings Date 03/05/26
Earnings Per Share ttm 0.40
EPS Growth vs. Prev Year -228.57%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

CTMX Ratios

Ratio
Price/Earnings ttm 10.50
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 44.49%
Return-on-Assets % 20.29%
Profit Margin % 23.08%
Debt/Equity 0.00
Price/Sales 5.15
Price/Cash Flow 11.60
Price/Book 6.45
Book Value/Share 0.65
Interest Coverage 2.08
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar